Kexing Biopharm's Licensed-In Product – Neratinib Maleate Tablets Receives Marketing Approval in Indonesia

Article source：Kexing BiopharmNov 20,2025View： 441

Recently, Neratinib Maleate Tablets (trade name in Indonesia: Hernera®), an innovative product independently developed by Convalife Pharmaceuticals (Shanghai) Co., Ltd. and licensed to Kexing Biopharm (Stock Code: 688136.SH), has been officially approved by the Indonesian National Agency for Drug and Food Control (BPOM) for marketing via the new drug registration pathway.

Hernera® is the first tyrosine kinase inhibitor (TKI) approved in Indonesia for extended adjuvant therapy and advanced treatment of HER2-positive early breast cancer. It helps fill the market gap in extended adjuvant therapy for early-stage HER2-positive breast cancer in the region, offering new hope to breast cancer patients.

In the field of breast cancer treatment, Kexing Biopharm has introduced multiple products, including albumin-bound paclitaxel, trastuzumab, eribulin, and palbociclib, comprehensively addressing the medication needs of physicians and patients while establishing a robust product cluster in breast cancer and other therapeutic areas.

In recent years, Kexing Biopharm has adhered to its “Innovation + Internationalization” strategy, focusing on the development of innovative drugs in oncology, autoimmune diseases, and other fields, while actively licensing excellent domestic pharmaceutical products for overseas markets. The company's internationalization efforts continue to accelerate. Since entering 2025, several licensed products have achieved substantial progress in overseas registrations, further enhancing the company's global competitiveness and delivering a broader range of treatment options to patients worldwide.

About Kexing

Kexing Biopharm (Stock Code: 688136.SH) is a multinational biopharmaceutical enterprise that engages in the R&D, manufacture and sales of innovative medicines of distinct modalities including recombinant proteins, antibodies, and targeted delivery therapies.

Through building cutting-edge technology platforms to advance the development of novel targeted therapies and drug delivery systems, Kexing strives to address unmet clinical needs in the areas of oncology, autoimmune and antiviral treatment, creating a significant and meaningful positive impact on patients' lives.

By adhering to the platform development model driven by the twin engines of “Innovation & Internationalization”, Kexing is committed to becoming a world leader in high-quality biopharmaceuticals, improving the health of patients worldwide.